FI109203B - Förfarande för framställning av en väsentligen ren heterodimer molekyl samt en farmaceutiskt komposition - Google Patents

Förfarande för framställning av en väsentligen ren heterodimer molekyl samt en farmaceutiskt komposition Download PDF

Info

Publication number
FI109203B
FI109203B FI933292A FI933292A FI109203B FI 109203 B FI109203 B FI 109203B FI 933292 A FI933292 A FI 933292A FI 933292 A FI933292 A FI 933292A FI 109203 B FI109203 B FI 109203B
Authority
FI
Finland
Prior art keywords
molecule
region
binding
domain
immunoglobulin
Prior art date
Application number
FI933292A
Other languages
English (en)
Finnish (fi)
Other versions
FI933292A0 (fi
FI933292A (fi
Inventor
Alejandro A Aruffo
Jeffrey A Ledbetter
Peter S Linsley
Nitin K Damle
Jr H Perry Fell
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI933292A0 publication Critical patent/FI933292A0/fi
Publication of FI933292A publication Critical patent/FI933292A/fi
Application granted granted Critical
Publication of FI109203B publication Critical patent/FI109203B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (13)

1. Förfarande för framställning av en väsentligen ren heterodimer molekyl, vilken molekyl omfattar tvä chi- 5 meriska kedjor, varav vardera omfattar en konstant domän av en tung kedja av immunoglobulin och ett bindningsomräde för en celladhesionsmolekyl, varvid vardera kedja omfattar ett bindningsomräde för olika celladhesionsmolekyler och varvid tvä kedjor av nämnda heterodimera molekyl anslutits 10 via den konstanta domänen av immunoglobulinets tunga kedja, kännetecknat av att ett första omräde, som för-mär binda sig tili en extracellulär domän av en första cellytsreceptor, och ett andra omräde, som förmär binda sig tili en extracellulär bindningsdomän av en andra cell-15 ytsreceptor, binds operativt tili varandra.
2. Förfarande enligt patentkrav 1, kännetecknat av att man framställer en molekyl vars respektive bindningsomräde har specificiteten för en extracellulär domän av en olik cellytsreceptor. . 20
3. Förfarande enligt patentkrav 1, känneteck- !„ nat av att man framställer en molekyl, varvid ätminstone _ ett av molekylens bindningsomräden har specificiteten för ' ett variabelt omräde för en antikropp som är riktad mot en : celladhesionsmolekyl. • 25
4. Förfarande enligt patentkrav 3, känneteck- .* n a t av att man framställer en molekyl, i vilken bind- ningsomrädet motsvarar specificiteten för det variabla om-| rädet av mAb 60.3.
.···, 5. Förfarande enligt patentkrav 3, känneteck- 30 nat av att man framställer en molekyl, som omfattar ett < t · konstant omräde för immunoglobulin vilket bundits opera-tivt tili tvä bindningsomräden, varvid respektive bind- : ningsomräde omfattar en extracellulär domän för olika • > * ,··*, cellytsreceptorer för celladhesionsmolekyler. 35
6. Förfarande enligt patentkrav 5 för framställ- ning av en heterodimer molekyl, kännetecknat av att 26 109203 man framställer en molekyl, i vilken immunoglobulinets konstanta omräde väsentligen motsvarar ett konstant omräde av human IgG.
7. Förfarande enligt patentkrav 5, känneteck-5 nat av att man framställer en molekyl, vars bindningsomräde omfattar en extracellular domän av ELAM-1, GMP140, ICAM-1 eller VCAM-1.
8. Förfarande enligt patentkrav 5, känneteck-n a t av att man framställer en molekyl, som omfattar ett 10 konstant omräde för ett IgG-fusionsprotein bundet tili om-rädet för de extracellulära domänerna av ELAM-1 och GMP140, ICAM-1 och ELAM-1, ICAM-1 och GMP140 eller VCAM-1 och GMP140.
9. Förfarande för framställning av en farmaceutisk 15 komposition, vilken komposition omfattar en heterodimer molekyl, som omfattar tvä chimera kedjor, varav vardera omfattar en konstant domän av en tung kedja av immunoglobulin och ett bindningsomräde för en celladhesionsmolekyl, varvid vardera kedja omfattar ett bindningsomräde för en . . 20 olik celladhesionsmolekyl och varvid tvä kedjor av nämnda heterodimera molekyl anslutits via den konstanta domänen '·' av immunoglobulinets tunga kedja, kännetecknat av att ett första omräde, som förmär binda sig tili en extra-: ".· cellulär domän av en första cellytsreceptor, och ett andra • 25 omräde, som förmär binda sig tili en extracellular bind- ningsdomän av en andra cellytsreceptor, binds operativt tili varandra och blandas tillsammans med en farmaceutiskt ,*. : godtagbar bärare.
,···, 10. Förfarande enligt patentkrav 9, känneteck- ’!* 30 nat av att man framställer en komposition i vilken ät- ,,[ minstone ett bindande omräde omfattar ett variabelt omräde '•."S för en antikropp som är riktad mot en celladhesionsmole- .·! : kyl.
11. Förfarande enligt patentkrav 9, känneteck-35 n at av att man framställer en komposition i vilken nämnda heterodimera molekyl omfattar ett konstant omräde för im- 27 109203 j munoglobulin vilket bundits operativt till tvä bindnings-omräden, varvid respektive bindningsomräde omfattar en extracellular domän för olika cellytsreceptorer för cellad- ! hesionsmolekyler. 5
12. Förfarande enligt patentkrav 11, känne- tecknat av att man framställer en komposition i vilken immunoglobulinets konstanta omräde väsentligen motsvarar ett konstant omräde av human IgG.
13. Förfarande enligt patentkrav 11, känne-10 tecknat av att man framställer en komposition i vilken ett bindningsomräde omfattar en extracellular domän av I ELAM-1, GMP140, ICAM-1 eller VCAM-1. • · » » · » » · I · » · · > · · i * i · • I I
FI933292A 1991-01-24 1993-07-21 Förfarande för framställning av en väsentligen ren heterodimer molekyl samt en farmaceutiskt komposition FI109203B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/645,522 US5709859A (en) 1991-01-24 1991-01-24 Mixed specificity fusion proteins
US64552291 1991-01-24
PCT/US1992/000616 WO1992012994A1 (en) 1991-01-24 1992-01-24 Mixed specificity fusion proteins
US9200616 1992-01-24

Publications (3)

Publication Number Publication Date
FI933292A0 FI933292A0 (fi) 1993-07-21
FI933292A FI933292A (fi) 1993-07-21
FI109203B true FI109203B (sv) 2002-06-14

Family

ID=24589356

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933292A FI109203B (sv) 1991-01-24 1993-07-21 Förfarande för framställning av en väsentligen ren heterodimer molekyl samt en farmaceutiskt komposition

Country Status (18)

Country Link
US (1) US5709859A (sv)
EP (1) EP0568645B1 (sv)
JP (1) JP3394534B2 (sv)
KR (1) KR100259061B1 (sv)
AT (1) ATE195254T1 (sv)
AU (1) AU648398B2 (sv)
CA (1) CA2099779C (sv)
DE (1) DE69231333T2 (sv)
DK (1) DK0568645T3 (sv)
ES (1) ES2148173T3 (sv)
FI (1) FI109203B (sv)
GR (1) GR3034524T3 (sv)
IE (1) IE920202A1 (sv)
IL (1) IL100731A (sv)
NO (1) NO313241B1 (sv)
NZ (1) NZ241357A (sv)
WO (1) WO1992012994A1 (sv)
ZA (1) ZA92467B (sv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
SG48892A1 (en) * 1993-01-25 1998-05-18 Dana Faber Cancer Inst Inc Chimeric L- and P-selectin by exchange of domains-uses thereof
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999049028A1 (en) 1998-03-23 1999-09-30 Genentech, Inc. Method of selection for genes encoding secreted and transmembrane proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
WO2000058501A2 (en) * 1999-03-26 2000-10-05 The Wistar Institute Novel genetic suppressor elements and methods of making the same
BR0010725A (pt) * 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (da) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
AU2002356496A1 (en) * 2001-05-16 2003-04-01 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
CA2565872C (en) * 2004-05-11 2016-06-21 Abgenomics Corporation T-cell death-inducing epitopes
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
UA97469C2 (uk) * 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
MX2011011044A (es) * 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
EP2536435B1 (en) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
US8426186B2 (en) 2010-04-16 2013-04-23 Centocor Ortho Biotech Inc. Engineered potato virus A nuclear inclusion protein
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
SG10201407036YA (en) 2010-11-05 2014-12-30 Transbio Ltd Markers of Endothelial Progenitor Cells and Uses Thereof
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017066530A1 (en) * 2015-10-15 2017-04-20 Anthrogensis Corporation Natural killer cells and ilc3 cells and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0365837B1 (en) * 1988-09-28 1995-08-02 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0583799A1 (en) * 1989-05-23 1994-02-23 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to ELAM-1 sialoglycoprotein antigen on the surface of activated endothelial cells
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules

Also Published As

Publication number Publication date
AU648398B2 (en) 1994-04-21
EP0568645A4 (en) 1994-09-28
DE69231333D1 (de) 2000-09-14
KR100259061B1 (ko) 2000-07-01
DE69231333T2 (de) 2001-01-18
WO1992012994A1 (en) 1992-08-06
EP0568645B1 (en) 2000-08-09
AU1339192A (en) 1992-08-27
NO932437L (no) 1993-09-17
IE920202A1 (en) 1992-07-29
IL100731A0 (en) 1992-09-06
ATE195254T1 (de) 2000-08-15
JPH06505388A (ja) 1994-06-23
GR3034524T3 (en) 2000-12-29
KR930703008A (ko) 1993-11-29
FI933292A0 (fi) 1993-07-21
EP0568645A1 (en) 1993-11-10
DK0568645T3 (da) 2000-09-18
CA2099779C (en) 2002-03-19
FI933292A (fi) 1993-07-21
JP3394534B2 (ja) 2003-04-07
IL100731A (en) 1997-07-13
NZ241357A (en) 1994-04-27
NO932437D0 (no) 1993-07-05
US5709859A (en) 1998-01-20
CA2099779A1 (en) 1992-07-25
ZA92467B (en) 1992-09-30
ES2148173T3 (es) 2000-10-16
NO313241B1 (no) 2002-09-02

Similar Documents

Publication Publication Date Title
FI109203B (sv) Förfarande för framställning av en väsentligen ren heterodimer molekyl samt en farmaceutiskt komposition
Diamond et al. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen.
IE83565B1 (en) Mixed specificity fusion proteins
Podolsky et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.
Mazzone et al. Leukocyte CD11/CD18 integrins: biological and clinical relevance
Teixido et al. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma.
Postigo et al. Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18.
Burkly et al. Signaling by vascular cell adhesion molecule‐1 (VCAM‐1) through VLA‐4 promotes CD3‐dependent T cell proliferation
Springer Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration
Damle et al. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes.
Languino et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway
Harlan Leukocyte adhesion deficiency syndrome: insights into the molecular basis of leukocyte emigration
Bazil et al. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand.
Issekutz Inhibition of lymphocyte endothelial adhesion and in vivo lymphocyte migration to cutaneous inflammation by TA-3, a new monoclonal antibody to rat LFA-1.
Lima et al. Immunophenotypic characterization of normal blood CD56+ lo versus CD56+ hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties
TICCHIONI et al. Integrin‐associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow
DeLisser et al. Platelet endothelial cell adhesion molecule 1 (PECAM-1/CD31): a multifunctional vascular cell adhesion molecule
Yan et al. Leukocyte recruitment into human skin transplanted onto severe combined immunodeficient mice induced by TNF-alpha is dependent on E-selectin.
Jääskeläinen et al. Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved.
Funaro et al. Stimulation of T cells via CD44 requires leukocyte-function-associated antigen interactions and interleukin-2 production
Laudanna et al. Ligation of members of the beta 1 or the beta 2 subfamilies of integrins by antibodies triggers eosinophil respiratory burst and spreading.
CA2220098A1 (en) Cd6 ligand
Kieffer et al. Uncoupling in the expression of platelet GP IIb/IIIa in human endothelial cells and K562 cells: Absence of immunologic crossreactivity between platelet GP IIb and the vitronectin receptor alpha chain
Springer Signals on endothelium for lymphocyte recirculation and leukocyte emigration: the area code paradigm
PT101148B (pt) Moleculas de fusao soluveis com especificidade de ligacao para as moleculas de adesao celulares